A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2017
At a glance
- Drugs TPI 287 (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions
- Acronyms TPI-287-4RT
- 03 Nov 2017 Data were presented in a Cortice Biosciences Media Release.
- 03 Nov 2017 According to a Cortice Biosciences media release, data were presented at the 2017 Clinical Trials on Alzheimers Disease (CTAD) conference.
- 10 Jun 2017 Biomarkers information updated